TPD52 and prostate carcinoma: Thus, PC-1/PrLZ is a novel candidate involved in DNA DSB repair and radioresistance, and targeting PC-1/PrLZ may offer promise for an effective method for enhancing the efficiency of radiation therapy for prostate cancer.